Listed

Keros Therapeutics, Inc.

KROSNasdaqCIK 1664710HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$30.9m, Q2 FY2026
Net income−$28.7m, Q2 FY2026
Keros Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$8.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure0.1Revenue, Q4 FY2023, three months to 2023-12-31$143.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2024, three months to 2024-03-31$83.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$37.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure0.4Revenue, Q3 FY2024, three months to 2024-09-30$388.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure3.0Revenue, Q4 FY2024, three months to 2024-12-31$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure211Revenue, Q1 FY2025, three months to 2025-03-31$211.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure18.2Revenue, Q2 FY2025, three months to 2025-06-30$18.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure14.3Revenue, Q3 FY2025, three months to 2025-09-30$14.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure0.4Revenue, Q4 FY2025, three months to 2025-12-31$385.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.4Revenue, Q1 FY2026, three months to 2026-03-31$367.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Research and development$m34.1Research and development, Q3 FY2023, three months to 2023-09-30$34.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure37.5Research and development, Q4 FY2023, three months to 2023-12-31$37.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure38.3Research and development, Q1 FY2024, three months to 2024-03-31$38.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure40.5Research and development, Q2 FY2024, three months to 2024-06-30$40.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure49.2Research and development, Q3 FY2024, three months to 2024-09-30$49.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure45.6Research and development, Q4 FY2024, three months to 2024-12-31$45.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure48.7Research and development, Q1 FY2025, three months to 2025-03-31$48.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure43.5Research and development, Q2 FY2025, three months to 2025-06-30$43.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure19.5Research and development, Q3 FY2025, three months to 2025-09-30$19.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure17.9Research and development, Q4 FY2025, three months to 2025-12-31$17.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure16.1Research and development, Q1 FY2026, three months to 2026-03-31$16.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure22.3Research and development, Q2 FY2026, three months to 2026-06-30$22.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Operating income$m(43.3)Operating income, Q3 FY2023, three months to 2023-09-30−$43.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure(46.5)Operating income, Q4 FY2023, three months to 2023-12-31−$46.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure(48.5)Operating income, Q1 FY2024, three months to 2024-03-31−$48.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure(50.4)Operating income, Q2 FY2024, three months to 2024-06-30−$50.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure(58.7)Operating income, Q3 FY2024, three months to 2024-09-30−$58.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(53.3)Operating income, Q4 FY2024, three months to 2024-12-31−$53.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure152Operating income, Q1 FY2025, three months to 2025-03-31$152.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(39.8)Operating income, Q2 FY2025, three months to 2025-06-30−$39.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(15.4)Operating income, Q3 FY2025, three months to 2025-09-30−$15.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(29.3)Operating income, Q4 FY2025, three months to 2025-12-31−$29.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(25.9)Operating income, Q1 FY2026, three months to 2026-03-31−$25.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(30.9)Operating income, Q2 FY2026, three months to 2026-06-30−$30.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Income tax$mnot reportednot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure0.3Income tax, Q4 FY2024, three months to 2024-12-31$300.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure10.0Income tax, Q1 FY2025, three months to 2025-03-31$10.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(2.2)Income tax, Q2 FY2025, three months to 2025-06-30−$2.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(1.4)Income tax, Q3 FY2025, three months to 2025-09-30−$1.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(1.5)Income tax, Q4 FY2025, three months to 2025-12-31−$1.5m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Net income$m(39.4)Net income, Q3 FY2023, three months to 2023-09-30−$39.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure(40.2)Net income, Q4 FY2023, three months to 2023-12-31−$40.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure(43.1)Net income, Q1 FY2024, three months to 2024-03-31−$43.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(45.3)Net income, Q2 FY2024, three months to 2024-06-30−$45.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(53.0)Net income, Q3 FY2024, three months to 2024-09-30−$53.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(46.0)Net income, Q4 FY2024, three months to 2024-12-31−$46.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure148Net income, Q1 FY2025, three months to 2025-03-31$148.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(30.7)Net income, Q2 FY2025, three months to 2025-06-30−$30.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(7.3)Net income, Q3 FY2025, three months to 2025-09-30−$7.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure(23.5)Net income, Q4 FY2025, three months to 2025-12-31−$23.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(23.7)Net income, Q1 FY2026, three months to 2026-03-31−$23.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(28.7)Net income, Q2 FY2026, three months to 2026-06-30−$28.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Diluted EPS$ per share(1.33)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figurenot reported(1.21)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure(1.25)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure(1.41)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figurenot reported3.62Diluted EPS, Q1 FY2025, three months to 2025-03-31$3.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(0.76)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(0.18)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figurenot reported(1.21)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(1.45)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Basic EPS$ per share(1.33)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.33 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figurenot reported(1.21)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure(1.25)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure(1.41)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figurenot reported3.66Basic EPS, Q1 FY2025, three months to 2025-03-31$3.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(0.76)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure(0.18)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figurenot reported(1.21)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(1.45)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure

Balance sheet

Cash and equivalents$257.6m, Q2 FY2026
Shareholders' equity$262.3m, Q2 FY2026
Keros Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m288Cash and equivalents, Q3 FY2023, at 2023-09-30$287.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure331Cash and equivalents, FY2023, at 2023-12-31$331.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-26, accession 0001664710-25-000018.Report this figure442Cash and equivalents, Q1 FY2024, at 2024-03-31$442.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure406Cash and equivalents, Q2 FY2024, at 2024-06-30$405.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure531Cash and equivalents, Q3 FY2024, at 2024-09-30$530.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure560Cash and equivalents, FY2024, at 2024-12-31$559.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure721Cash and equivalents, Q1 FY2025, at 2025-03-31$720.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure690Cash and equivalents, Q2 FY2025, at 2025-06-30$690.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure693Cash and equivalents, Q3 FY2025, at 2025-09-30$693.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure287Cash and equivalents, FY2025, at 2025-12-31$287.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure281Cash and equivalents, Q1 FY2026, at 2026-03-31$281.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure258Cash and equivalents, Q2 FY2026, at 2026-06-30$257.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Current assets$m304Current assets, Q3 FY2023, at 2023-09-30$304.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-06, accession 0001664710-23-000066.Report this figure347Current assets, FY2023, at 2023-12-31$347.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-26, accession 0001664710-25-000018.Report this figure463Current assets, Q1 FY2024, at 2024-03-31$463.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001664710-24-000039.Report this figure433Current assets, Q2 FY2024, at 2024-06-30$432.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001664710-24-000068.Report this figure552Current assets, Q3 FY2024, at 2024-09-30$552.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure589Current assets, FY2024, at 2024-12-31$588.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure760Current assets, Q1 FY2025, at 2025-03-31$759.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure733Current assets, Q2 FY2025, at 2025-06-30$732.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure719Current assets, Q3 FY2025, at 2025-09-30$719.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure315Current assets, FY2025, at 2025-12-31$315.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure291Current assets, Q1 FY2026, at 2026-03-31$290.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure267Current assets, Q2 FY2026, at 2026-06-30$266.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Total assets$m326Total assets, Q3 FY2023, at 2023-09-30$326.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-06, accession 0001664710-23-000066.Report this figure370Total assets, FY2023, at 2023-12-31$370.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-26, accession 0001664710-25-000018.Report this figure486Total assets, Q1 FY2024, at 2024-03-31$485.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001664710-24-000039.Report this figure455Total assets, Q2 FY2024, at 2024-06-30$455.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001664710-24-000068.Report this figure579Total assets, Q3 FY2024, at 2024-09-30$579.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure616Total assets, FY2024, at 2024-12-31$615.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure785Total assets, Q1 FY2025, at 2025-03-31$784.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure757Total assets, Q2 FY2025, at 2025-06-30$757.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure743Total assets, Q3 FY2025, at 2025-09-30$742.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure338Total assets, FY2025, at 2025-12-31$338.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure312Total assets, Q1 FY2026, at 2026-03-31$312.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure288Total assets, Q2 FY2026, at 2026-06-30$287.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Current liabilities$m16.7Current liabilities, Q3 FY2023, at 2023-09-30$16.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-06, accession 0001664710-23-000066.Report this figure24.4Current liabilities, FY2023, at 2023-12-31$24.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-26, accession 0001664710-25-000018.Report this figure18.7Current liabilities, Q1 FY2024, at 2024-03-31$18.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001664710-24-000039.Report this figure21.2Current liabilities, Q2 FY2024, at 2024-06-30$21.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001664710-24-000068.Report this figure29.0Current liabilities, Q3 FY2024, at 2024-09-30$29.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure27.5Current liabilities, FY2024, at 2024-12-31$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure39.4Current liabilities, Q1 FY2025, at 2025-03-31$39.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure34.7Current liabilities, Q2 FY2025, at 2025-06-30$34.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure24.1Current liabilities, Q3 FY2025, at 2025-09-30$24.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure20.4Current liabilities, FY2025, at 2025-12-31$20.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure12.9Current liabilities, Q1 FY2026, at 2026-03-31$12.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure12.2Current liabilities, Q2 FY2026, at 2026-06-30$12.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Total liabilities$m30.4Total liabilities, Q3 FY2023, at 2023-09-30$30.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-06, accession 0001664710-23-000066.Report this figure37.8Total liabilities, FY2023, at 2023-12-31$37.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-26, accession 0001664710-25-000018.Report this figure31.9Total liabilities, Q1 FY2024, at 2024-03-31$31.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001664710-24-000039.Report this figure34.1Total liabilities, Q2 FY2024, at 2024-06-30$34.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001664710-24-000068.Report this figure46.4Total liabilities, Q3 FY2024, at 2024-09-30$46.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure44.3Total liabilities, FY2024, at 2024-12-31$44.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure55.7Total liabilities, Q1 FY2025, at 2025-03-31$55.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure50.4Total liabilities, Q2 FY2025, at 2025-06-30$50.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure39.2Total liabilities, Q3 FY2025, at 2025-09-30$39.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure34.9Total liabilities, FY2025, at 2025-12-31$34.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure26.7Total liabilities, Q1 FY2026, at 2026-03-31$26.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure25.3Total liabilities, Q2 FY2026, at 2026-06-30$25.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure
Shareholders' equity$m296Shareholders' equity, Q3 FY2023, at 2023-09-30$295.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure332Shareholders' equity, FY2023, at 2023-12-31$332.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-04, accession 0001664710-26-000018.Report this figure454Shareholders' equity, Q1 FY2024, at 2024-03-31$453.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure421Shareholders' equity, Q2 FY2024, at 2024-06-30$420.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure533Shareholders' equity, Q3 FY2024, at 2024-09-30$532.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure572Shareholders' equity, FY2024, at 2024-12-31$571.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure729Shareholders' equity, Q1 FY2025, at 2025-03-31$728.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure707Shareholders' equity, Q2 FY2025, at 2025-06-30$706.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure704Shareholders' equity, Q3 FY2025, at 2025-09-30$703.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure303Shareholders' equity, FY2025, at 2025-12-31$303.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure286Shareholders' equity, Q1 FY2026, at 2026-03-31$285.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure262Shareholders' equity, Q2 FY2026, at 2026-06-30$262.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure

Cash flow

Operating cash flow−$20.4m, Q2 FY2026
Capital expenditure$155.0k, Q2 FY2026
Keros Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(34.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$34.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001664710-24-000091. Derived: 9-month figure less the 6-month figure.Report this figure(25.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$25.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure(44.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$44.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure(39.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$39.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0001664710-25-000070. Derived: 6-month figure less the 3-month figure.Report this figure(30.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$30.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001664710-25-000089. Derived: 9-month figure less the 6-month figure.Report this figure(46.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$46.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure161Operating cash flow, Q1 FY2025, three months to 2025-03-31$161.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(29.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$29.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001664710-26-000049. Derived: 6-month figure less the 3-month figure.Report this figure3.2Operating cash flow, Q3 FY2025, three months to 2025-09-30$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001664710-25-000089. Derived: 9-month figure less the 6-month figure.Report this figure(27.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$27.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure(3.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure(20.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$20.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-03, accession 0001664710-26-000049. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.6Capital expenditure, Q3 FY2023, three months to 2023-09-30$550.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001664710-24-000091. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2023, three months to 2023-12-31$541.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-26, accession 0001664710-25-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.9Capital expenditure, Q1 FY2024, three months to 2024-03-31$946.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$310.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0001664710-25-000070. Derived: 6-month figure less the 3-month figure.Report this figure0.4Capital expenditure, Q3 FY2024, three months to 2024-09-30$386.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001664710-25-000089. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$289.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.6Capital expenditure, Q1 FY2025, three months to 2025-03-31$565.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure0.7Capital expenditure, Q2 FY2025, three months to 2025-06-30$720.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001664710-26-000049. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$132.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001664710-25-000089. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-04, accession 0001664710-26-000018. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$73.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$155.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-03, accession 0001664710-26-000049. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)19.80m, Q2 FY2026
Keros Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares25.5Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3025,549,701 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-06, accession 0001664710-23-000066.Report this figure28.4Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3128,369,453 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001664710-24-000039.Report this figure29.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3029,602,458 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001664710-24-000068.Report this figure29.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3029,668,247 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001664710-24-000091.Report this figure35.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3135,685,422 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001664710-25-000046.Report this figure36.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3036,103,187 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0001664710-25-000070.Report this figure37.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3037,590,727 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure41.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3141,021,325 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure40.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3040,612,907 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure40.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3040,623,364 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001664710-25-000089.Report this figure19.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3119,629,906 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001664710-26-000030.Report this figure19.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3019,800,322 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure

Shares outstanding: 19.83mShares outstanding, period not labelled, at 2026-07-2719,827,188 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-03, accession 0001664710-26-000049.Report this figure at Jul 27, 2026, from the cover of the 10-Q filed Aug 3, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.